Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

Comparison between plasma concentrations of PEG–trastuzumab in non lymph cannulated and cannulated rats after intravenous and subcutaneous dosing. Observed vs individual or population fits of plasma ...

By comparison, they found that it took only nine hours for blood glucose levels to return to their original values in control models treated with insulin by the normal route of subcutaneous injection.